Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana (HUM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $1.62 per share a year ago.

Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates

The health insurer says 2024 earnings will be barely half of estimates due to higher Medicare Advantage costs.

Humana Dives On Huge 2024 Earnings Warning

Amgen

Cigna

Elevance Health Inc

Incyte

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.

5 top healthcare stocks for earnings growth in 2024

Humana Inc.'s stock HUM, -1.26% fell 17% early Thursday, after the managed care company's quarterly loss widened amid soaring medial costs. Humana posted a loss of $491 million, or $4.42 a share, for the quarter, wider than the loss of $71 million, or 12 cents a share, posted in the year-earlier period.

Humana's stock tumbles 17% as quarterly loss widens amid soaring medical costs

Humana Inc forecast 2024 profit sharply below Wall Street estimates on Thursday as it expects higher costs within its Medicare Advantage plans for older adults to persist into 2024, sending the company's shares plunging 15% premarket.

Humana forecasts dismal 2024 profit on high medical costs

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health insurer and health care services company Humana Inc. (NYSE: HUM) announced today that it has named David Dintenfass as President of Enterprise Growth. In this new role, Dintenfass will have responsibility for leading the company's growth plan with a primary focus on customer acquisition, retention, and experience. The creation of this position, and its emphasis on the customer and digital experience, will help Humana deliver on its long-term stra.

Humana Appoints President of Enterprise Growth

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings (loss) per share (EPS) for the quarter ended December 31, 2023 (4Q23) versus the quarter ended December 31, 2022 (4Q22) and for the year ended December 31, 2023 (FY 2023) versus the year ended December 31, 2022 (FY 2022) as noted in the tables below. Consolidated (loss) income before income taxes and equity in net earnings (pretax results) In millions 4Q23 (a) 4Q22 (a) FY 2023 (.

Humana Reports Fourth Quarter 2023 Financial Results; Provides Initial Full Year 2024 Financial Guidance

The company reports earnings before the market open Thursday.

Humana Earnings Are Soon. The Focus Will Be Medicare Advantage.

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced that the company has signed agreements for in-network provider status with Humana Inc. Under the agreement, Humana's over 13 million members will have improved access to Tempus' portfolio of molecular profiling tests in accordance with their medical policies, expanding precision oncology care throughout the country. The company offers a comprehensive molecular profiling portfolio which.

Tempus is Now an In-Network Provider for Humana, Expanding Access to its Next-Generation Sequencing Tests

Evaluate the expected performance of Humana (HUM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Ahead of Humana (HUM) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.

Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?

Humana stock price experienced a major downward correction after the company issued a profit warning this week. HUM shares have fallen from ~$520 in November, to

Humana: Another Profit Warning - Should Investors Take Heed?

Humana issued a surprise press release today lowering its 2023 earnings guidance. The company cited rising Medicare Advantage costs in November and December.

Why Humana Stock Fell Today

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2023 (4Q23), as well as prepared management remarks (in PDF format), on Thursday, January 25, 2024, at approximately 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024. The call was originally scheduled for Monday, February 5, but was.

Humana Inc. Reschedules Fourth Quarter 2023 Earnings Call to Thursday, January 25, at 9:00 a.m. E.T.

CVS Health

UnitedHealth Group

A sharp spike in hospital and doctor office visits among older Americans is raising questions about the program.

Humana and Other Insurers Bet Big on Medicare Advantage. Now the Risks Are Coming Into Focus.

The healthcare sector is taking a hit after Humana Inc (NYSE:HUM) today slashed its 2023 profit outlook, citing higher-than-anticipated medical costs in the fourth quarter.

Healthcare Stocks Slide After Humana Forecast

Apple

Taiwan Semiconductor Manufacturing

The major U.S. equity indexes were mixed at midday Thursday as tech stocks gained while bond yields climbed. The S&P 500 and Nasdaq were higher, while the Dow was lower.

Top Stock Movers Now: Apple, Humana, TSMC, and More

Humana Inc. (HUM) shares plunged Thursday after the health insurance provider warned that full-year profit will be negatively affected by higher medical-care costs for Medicare patients.

Humana Stock Plunges More Than 10% to Two-Year Low on Medicare Medical Cost Warning

Humana slashed its Q4 earnings outlook on higher medical costs and warned about weak Medicare Advantage enrollment.

Humana Stock Falls Ill On This Warning; UNH, CVS Catch Virus

Humana Inc. shares HUM, +2.04% dropped 14% premarket on Thursday after the giant health insurer slashed its full-year 2023 earnings guidance and flagged rising medical costs and slower than expected 2024 Medicare Advantage enrollment growth.

Humana stock tumbles as Medicare Advantage growth disappoints

Humana expects fiscal 2023 adjusted earnings of about $26.09 a share, down from the company's prior estimates of $28.25.

Humana Stock Crumbles as Forecast Cut on Higher Medical Costs

Humana is the fifth-largest player in the healthcare plans industry with a market cap of $62 billion. Despite recent stock performance, Humana has outperformed the S&P 500 over the last ten and fifteen years. The company's strong growth in memberships and positive industry outlook make it a potentially solid Strong Buy investment opportunity.

Humana: My Oh My, Another Strong Buy

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Humana (HUM) is a Strong Growth Stock

Insulet

Health Care Select Sector SPDR Fund

Zoetis

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Citigroup

If the economy were to start showing clear signs of weakening, defensive healthcare stocks such as UnitedHealth, Humana, and Cigna would look relatively attractive.

News for Humana Stock (HUM)